Dose-response relationship for inhaled corticosteroids and the add-on effect of long-acting β2-adrenergic receptor agonists in adult chronic asthmatics

Allergology International

Volumn 53, Issue 4, 2004, Pages 291-299

  Hojo, Masayuki ^a   Kudo, Koichiro ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Add on effect; Bronchial asthma; Dose response relationship; Inhaled corticosteroids; Long acting 2 adrenergic receptor agonist

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; STEROID; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CATARACT; CLINICAL TRIAL; DISEASE CONTROL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; GROWTH DISORDER; HUMAN; LONG TERM CARE; META ANALYSIS; OPEN ANGLE GLAUCOMA; OSTEOPOROSIS; OUTCOMES RESEARCH; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 11144289985     PISSN: 13238930     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1592.2004.00351.x     Document Type: Review

References (56)

1. National Heart, Lung, and Blood Institute, National Institutes of Health, World Heolth Organization. Global Strategy for Asthma Management and Prevention, Revised. NIH publication no. 02-3659. Bethesda: National Institutes of Health. 2002.
2. National Asthma Education and Prevention Program, Expert Panel Report. Guidelines for the Diagnosis and Management of Asthma: Update on Selected Topics, 2002. J. Allergy Clin. Immunol. 2002; 110S (Suppl.): 141-219.
3. Ministry of Health and Welfare, Japan. Asthma prevention and management guidelines. Int. Arch. Allergy Immunol. 2000; 121 (Suppl. 1): 1-77.
4. Suissa S, Ernst P. Use of anti-inflammatory therapy and asthma mortality in Japan. Eur. Respir. J. 2003; 21: 101-4.
5. Gaddie J, Reid IW, Skinner C, Petrie GR, Sinclair DJ, Palmer KN. Aerosol beclomethasone dipropionate: A dose-response study in chronic bronchial asthma. Lancet 1973; ii: 280-1.
6. Brompton Hospital and Medical Research Council. Double blind trial comparing two dosage schedules of beclomethasone dipropionate aerosol with placebo in chronic bronchial asthma. J. Dis. Chest 1979; 73: 121-3.
7. Hummel S, Lehtonen L, Adolph J et al. Comparison of oral-steroid-sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma. Lancet 1992; 340: 1483-7.
8. Kuda K, Hajo M, Kobe J. Inhaled beclomethasone in long-term management of asthma: Optimal dose and optimal duration of treatment. Nihon Kyobu Shikkan Gakkai Zasshi 1995; 33: 956-65 (in Japanese).
9. Kudo K, Tanabe N, Kabe J. High-dose inhaled beclomethasone in long-term management of chronic severe asthma: Usefulness and dose-dependence. Nihon Kyobu Shikkan Gakkai Zasshi 1996; 34: 536-44 (in Japanese).
10. Adams N, Bestall J, Jones P. Inhaled beclomethasone at different doses for long term asthma. Cochrane Library 2001 (on-line): http://www.update- software.com/abstracts/ ab002879.htm
11. Busse WW, Chervinsky P, Condemi J et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J. Allergy Clin. Immunol. 1998; 101: 457-63.
12. McFadden ER, Casale TB, Edwards TB et al. Administration of budesonide once daily by means of turbuhaler to subjects with stable asthma. J. Allergy Clin. Immunol. 1999; 104: 46-52.
13. Miyamoto T, Takahashi T, Nakajima S et al. Efficacy of budesonide Turbuhaler compared with that of beclomethasone dipropionate pMDI in Japanese patients with moderately persistent asthma. Respirology 2001; 6: 27-35.
14. Miyamoto T, Takahashi T, Nakajima S et al. A double-blind, placebo-controlled dose-response study with budesonide Turbuhaler in Japanese asthma patients. Japanese Pulmicort Turbuhaler Study Group. Respirology 2000; 5: 247-56.
15. Jatakanon A, Kharitonov S, Lim S, Barnes PJ. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999; 54: 108-14.
16. Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J. Allergy Clin. Immunol. 1998; 102: 536-51.
17. Dahl R, Lundback B, Malo JL et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest 1993; 104: 1352-8.
18. Chervinsky P, van As A, Bronsky EA et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. J. Allergy Clin. Immunol. 1994; 94: 676-83.
19. Wolfe JD, Selner JC, Mendelson LM, Hampel Jr F, Schaberg A. Effectiveness of fluticasone propionate in patients with moderate asthma: A dose-ranging study. Clin. Ther. 1996; 18: 635-46.
20. Nathan RA, Li JT, Finn A et al. A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest 2000; 118: 296-302.
21. Welch M, Bernstein D, Gross G, Kane RE, Banerji D. A controlled trial of chlorofluorocarbon-free triamcinolane acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Azmacort HFA Study Group. Chest 1999; 116: 1304-12.
22. Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K, Harrison JE. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J. Allergy Clin. Immunol. 2000; 106: 485-92.
23. Pedersen S, Hansen OR Budesonide treatment of moderate and severe asthma in children: A dose-response study. J. Allergy Clin. Immunol. 1995; 95: 29-33.
24. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52: 1-34.
25. Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL. A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin. Ther. 2002; 24: 1-20.
26. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: New developments. Am. J. Respir. Crit. Care Med. 1998; 157 (Suppl.): S1-53.
27. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch. Intern. Med. 1999; 159: 941-55.
28. Toagood JH. Side effects of inhaled corticosteroids. J. Allergy Clin. Immunol. 1998; 102: 705-13.
29. Kelly HW. Potential adverse effects of the inhaled corticosteraids. J. Allergy Clin. Immunol. 2003; 112: 469-78.
30. Todd GRG, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch. Dis. Child 2002; 87: 457-61.
31. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N. Engl. J. Med. 2000; 343: 1054-63.
32. Pedersen S. Do inhaled corticosteroids inhibit growth in children? Am. J. Respir. Crit. Care Med. 2001; 164: 521-35.
33. Martin RJ, Szefler SJ, Chinchilli VM et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am. J. Respir. Crit. Care Med. 2002; 165: 1377-83.
34. Nielsen LP, Dahl R Therapeutic ratio of inhaled corticosteroids in adult asthma: A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am. J. Respir. Crit. Care Med. 2000; 162: 2053-7.
35. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 1997; 337: 1405-11.
36. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219-24.
37. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368-73.
38. Ind PW, Dal Negro R, Colman N, Fletcher CP, Browning DC, James MH. Inhaled fluticasone propionate and salmeterol in moderate adult asthma. II. Exacerbations. Am. J. Respir. Crit. Care Med. 1998; 157: A415 (Abstract).
39. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 1996; 153: 1481-8.
40. Kelsen SG, Church NL, Gillman SA, Lanier BQ, Emmett AH, Rickard KA. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: A randomized clinical trial. J. Asthma 1999; 36: 703-15.
41. Murray JJ, Church NL, Anderson WH, Bernstein DI, Wenzel SE, Emmett A. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticasteroid dose increases. Allergy Asthma Proc. 1999; 20: 173-80.
42. Kalberg CJ, Nelson H, Yancey S, Petrocella V, Emmett AH, Rickard KA. A comparison of added salmeterol versus increased-dose fluticasone in patients symptomatic on low-dose fluticasone. J. Allergy Clin. Immunol. 1998; 101: 56 (Abstract).
43. Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Ann. Allergy Asthma Immunol. 1999; 82: 383-9.
44. van Noord JA, Schreurs AJM, Mol SJM, Mulder PGH. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999; 54: 207-12.
45. Vermetten FAAM, Boermans AJM, Luiten WDVF, Mulder PGH, Vermue NA. Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids. J. Asthma 1999; 36: 97-106.
46. 2-agonist over three months on airway wall vascular remodeling in asthma. Am. J. Respir. Crit. Care Med. 2001; 164: 117-21.
47. Busse W, Koenig SM, Oppenheimer J et al. Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily. J. Allergy Clin. Immunol. 2003; 111: 57-65.
48. McIvor RA, Pizzichini E, Turner MO, Hussock P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 1998; 158: 924-30.
49. Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am. J. Respir. Crit. Care Med. 2000; 161: 996-1001.
50. Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J. Allergy Clin. Immunol. 1999; 103: 1075-80.
51. Lofdahl CG, Reiss TF, Leff JA et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319: 87-90.
52. Laviolette M, Malmstrom K, Lu S et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am. J. Respir. Crit. Care Med. 1999; 160: 1862-8.
53. Fish JE, Israel E, Murray JJ et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120: 423-30.
54. Nelsan HS, Busse WW, Kerwin E et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J. Allergy Clin. Immunol. 2000; 106: 1088-95.
55. Bjermer L, Bisgaard H, Bousquet J et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: One year, double blind, randomised, comparative trial. BMJ 2003; 327: 891-6.
56. Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline: Meta-analysis of nine controlled studies. Respir. Med. 1998; 92: 256-63.